On February 17, 2022, Chen, Xiangyang; Pang, Yucheng published a patent.Electric Literature of 29704-38-9 The title of the patent was Pyridazine-3-carboxamide compound, its preparation and application in medicine. And the patent contained the following:
Disclosed in the present invention are a pyridazine-3-formamide compound suitable for inhibiting or regulating the Janus kinase (JAK), in particular tyrosine kinase 2 (TYK2), and a preparation method therefor and the medical use thereof. In particular, disclosed in the present invention are a compound as represented by general formula I and a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof, a method for treating and/or preventing Janus kinase-mediated related diseases, in particular autoimmune diseases, inflammatory diseases and cancers, by means of using the compound or the pharmaceutically acceptable salt thereof, and a method for preparing the compound or the pharmaceutically acceptable salt thereof. Each substituent of general formula I has the same definition as that in the description. The experimental process involved the reaction of tert-Butyl 2-(4-nitrophenyl)acetate(cas: 29704-38-9).Electric Literature of 29704-38-9
The Article related to pyridazine carboxamide preparation janus kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Electric Literature of 29704-38-9
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics